Literature DB >> 16489358

Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.

H Watanabe1, T Watanabe, H Suzuya, Y Wakata, M Kaneko, T Onishi, Y Okamoto, T Abe, Y Kawano, S Kagami, Y Takaue.   

Abstract

In 56 pediatric and adolescent patients (median age 7 years, range 1-21) with various solid tumors, peripheral blood stem cells (PBSC) were mobilized with granulocyte colony-stimulating factor (G-CSF) alone, and the yields of PBSC and engraftment kinetics following autologous peripheral blood stem cell transplantation (PBSCT) were evaluated retrospectively. Granulocyte colony-stimulating factor (10 microg/kg) was injected subcutaneously for mobilization when patients showed no influence of previous chemotherapy, and administration was continued for 5 days. The peaks of CD34+ cells and colony-forming units-granulocyte/macrophage in the blood were observed on days 4 through 6 of G-CSF administration in all patients. Peripheral blood stem cell harvest was commenced on day 5 of G-CSF treatment. Compared to the results in patients mobilized by chemotherapy plus G-CSF (N=18), the progenitor cell yields were lower in patients mobilized with G-CSF alone. However, there were no significant differences in WBC and ANC engraftment compared to the chemotherapy plus G-CSF mobilization group. Platelet recovery following autologous PBSCT was delayed in patients mobilized with G-CSF alone. The median time taken for ANC and platelet counts to reach 0.5 x 10(9) and 20 x 10(9)/l was 12 days (range: 9-28) and 15 days (8-55), respectively, in all patients who received PBSC mobilized by G-CSF alone. In summary, mobilization with G-CSF alone can mobilize sufficient CD34+ cells for successful autografting and sustained hematological reconstitution in pediatric and adolescent patients with solid tumors, and even in heavily pre-treated patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489358     DOI: 10.1038/sj.bmt.1705304

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Proliferation and differentiation potential of cryopreserved human skin-derived precursors.

Authors:  M Bakhtiari; K Mansouri; Y Sadeghi; A Mostafaie
Journal:  Cell Prolif       Date:  2012-01-20       Impact factor: 6.831

2.  Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation.

Authors:  Alberto Olaya Vargas; Roberto Rivera Luna; Martin Perez Garcia; Rocio Cárdenas Cardos; Liliana Velasco Hidalgo; Doris Lordméndez Jácome; Mariana Campos Gutiérrez
Journal:  Rev Bras Hematol Hemoter       Date:  2013

3.  Mobilization and collection of CD34(+) cells for autologous transplantation of peripheral blood hematopoietic progenitor cells in children: analysis of two different granulocyte-colony stimulating factor doses.

Authors:  Kátia Aparecida de Brito Eid; Eliana Cristina Martins Miranda; Simone Dos Santos Aguiar
Journal:  Rev Bras Hematol Hemoter       Date:  2015-02-17

4.  Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization.

Authors:  Farrukh T Awan; S Thomas Kochuparambil; David Deremer; Aaron Cumpston; Michael Craig; Anand Jillella; Mehdi Hamadani
Journal:  J Oncol       Date:  2012-04-10       Impact factor: 4.375

Review 5.  Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.

Authors:  Saeed Mohammadi; Ashraf Malek Mohammadi; Mohsen Nikbakht; Amir Hossein Norooznezhad; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.